FDA Approves First “Smart Capsule” for Obesity

The Allurion Gastric Balloon System, a first-of-its-kind "Smart Capsule" designed to provide a non-invasive alternative to traditional bariatric surgery and long-term pharmacotherapy was granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA). The Smart Capsule has been implemented in more than 200,000 patients, the company noted, with data on its use documented in over 30 peer-reviewed medical journals. ^1,2

The device is indicated for patients with a body mass index (BMI) between 30 and 40 kg/m², a demographic that includes approximately 80 million Americans. Shelby Sullivan, MD, professor of medicine at the Geisel School of Medicine at Dartmouth University and principal investigator on the AUDACITY FDA pivotal trial said, “Obesity is a critical issue in the United States, and many patients are looking for alternatives or complements to existing options, including GLP-1 medications.”

Unlike traditional gastric balloons require endoscopy and anesthesia for placement and removal, the Allurion Smart Capsule is swallowed by the patient during a 15-minute office visit. Once the capsule reaches the stomach, it is filled with fluid, where it resides for approximately 4 months to induce satiety and reduce caloric intake.

The device features a patented release valve that automatically opens after the 4-month treatment period, allowing the balloon to empty and pass out of the body naturally. This design eliminates the need for a secondary procedure for removal. For patients requiring further intervention, a second capsule can be administered 2 months after the passage of the first.

The approval comes at a time when many patients are seeking alternatives to GLP-1 receptor agonists. Data from previous studies have shown that 65% of patients discontinue GLP-1 medications within the first year, often due to side effects, leading to rapid weight regain.

“Our goal is to deliver patients metabolically healthy weight loss by helping them lose weight, keep it off, and maintain muscle. The Allurion Smart Capsule offers a safe and effective alternative to GLP-1s and bariatric surgery, and it should become a standard tool in the comprehensive treatment of obesity in the United States,” said Shantanu Gaur, MD, founder and chief executive officer.

The AUDACITY trial evaluated the safety and efficacy of the Allurion Gastric Balloon System in a multicenter, randomized controlled study involving 550 participants. Patients were randomized 1:1 to receive either two cycles of the Allurion Balloon plus care or moderate-intensity lifestyle therapy alone.

Results from the AUDACITY FDA pivotal trial, along with real-world data from patients treated outside the US, supported the approval. Clinical highlights include:

• Standalone Weight Loss: Patients achieved an average total body weight loss (TBWL) of 14% when the balloon was combined with Allurion’s AI-powered behavior change program.

• Sequential Therapy: 2 cycles of therapy resulted in over 20% TBWL.

• Combination Therapy: When used in conjunction with a low dose of GLP-1s, patients also achieved over 20% TBWL with favorable improvements in muscle mass.

• Serious Adverse Events (SAEs): The reported SAE rate for Allurion Balloon recipients was 3.1%.

• Comparative Safety: This 3.1% rate is the lowest reported in any FDA pivotal trial for a liquid-filled intragastric balloon system to date

Managing the "critical issue" of obesity and the lack of a requirement for long-term medication make it an attractive option for patients. Sullivan, MD, stated, “The AUDACITY trial results coupled with the real-world experience outside the United States demonstrate the product’s safety and efficacy. The solution offers an option that many people are looking for. It has a finite time in the body, is repeatable when necessary, and it does not require patients to take long-term medications for weight loss. As a standalone or complementary tool to fight obesity, Allurion has an important role to play for both patients and physicians.”

References

1. Allurion Technologies, Inc. Allurion Receives U.S. FDA Approval. Businesswire.com. Published February 23, 2026. Accessed February 23, 2026. https://www.businesswire.com/news/home/20260223930098/en/Allurion-Receives-U.S.-FDA-Approval

2. Allurion Announces Positive Topline Results From AUDACITY Trial. Allurion.com. Published 2023. Accessed February 23, 2026. https://investors.allurion.com/news/news-details/2025/Allurion-Announces-Positive-Topline-Results-From-AUDACITY-Trial/default.aspx